tiprankstipranks
Advertisement
Advertisement

BMY Stock Latest News

Acting FDA head vows to block political interference, Endpoint News says
The FlyActing FDA head vows to block political interference, Endpoint News says
56m ago
AZN
BMY
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
PremiumRatings
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
8h ago
BMY
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
PremiumThe Fly
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
1d ago
BMY
RCUS
Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors
PremiumCompany Announcements
Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors
2d ago
BMY
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
2d ago
AZN
BMY
Bristol Myers, SystImmune announce results from analyses of iza-bren studies
PremiumThe FlyBristol Myers, SystImmune announce results from analyses of iza-bren studies
2d ago
BMY
Bristol Myers: Opdivo in combination with AVD receives expanded EU label
Premium
The Fly
Bristol Myers: Opdivo in combination with AVD receives expanded EU label
3d ago
BMY
Bristol Myers says FDA accepts sNDA for Camzyos
Premium
The Fly
Bristol Myers says FDA accepts sNDA for Camzyos
3d ago
BMY
BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial
PremiumThe Fly
BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial
4d ago
BMY
BNTX
Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside
PremiumCompany Announcements
Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside
6d ago
BMY
Bristol-Myers Squibb Backs New Cell Therapy Combo in Early GI Cancer Trial
PremiumCompany Announcements
Bristol-Myers Squibb Backs New Cell Therapy Combo in Early GI Cancer Trial
6d ago
BMY
C4 Therapeutics jumps after Bristol Myers myeloma data
PremiumThe Fly
C4 Therapeutics jumps after Bristol Myers myeloma data
6d ago
BMY
CCCC
Why Penny Stock Replimune (REPL) Nearly Doubled Today
PremiumMarket NewsWhy Penny Stock Replimune (REPL) Nearly Doubled Today
6d ago
BMY
REPL
Bristol Myers says CELMoD mezigdomide reduces risk of disease progression by 52%
Premium
The Fly
Bristol Myers says CELMoD mezigdomide reduces risk of disease progression by 52%
6d ago
BMY
Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential
Premium
Ratings
Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential
6d ago
BMY
BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
PremiumMarket News
BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
15d ago
BMY
LLY
Bristol Myers announces strategic agreement with Anthropic
PremiumThe Fly
Bristol Myers announces strategic agreement with Anthropic
15d ago
BMY
Bristol-Myers Squibb’s REACH Study in China: What Real-World Luspatercept Data Could Mean for BMY Investors
PremiumCompany Announcements
Bristol-Myers Squibb’s REACH Study in China: What Real-World Luspatercept Data Could Mean for BMY Investors
16d ago
BMY
Trump Trade: Trump announces expansion of TrumpRx.gov
PremiumThe Fly
Trump Trade: Trump announces expansion of TrumpRx.gov
16d ago
AZN
BMY
Trump to announce ‘dramatic expansion’ of TrumpRx offerings, CNBC says
PremiumThe FlyTrump to announce ‘dramatic expansion’ of TrumpRx offerings, CNBC says
17d ago
AZN
BMY
Davis to become acting director of CDER after Hoeg exit, Bloomberg says
Premium
The Fly
Davis to become acting director of CDER after Hoeg exit, Bloomberg says
20d ago
AZN
BMY
Bristol-Myers Squibb Advances Navlimetostat With Key Phase 1 Tablet Study
Premium
Company Announcements
Bristol-Myers Squibb Advances Navlimetostat With Key Phase 1 Tablet Study
21d ago
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >